Eckert & Ziegler Strahlen- und Medizintechnik AG

M&A Activity • Mar 13, 2009

News Details

Corporate | 13 March 2009 10:48

Eckert & Ziegler sells Milan-based contrast media business

ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Disposal

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Berlin, 13.03.2009. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE0005659700) has sold its Milan-based contrast media business and sold all
the shares in its subsidiary company Eckert & Ziegler f-con Pharma Italia
s.r.l. (FCI) to the Italian A.C.O.M.- Advanced Center Oncology Macerata
SPA. The shares were sold for a nominal price, however,
through the transfer of certain payment obligations to the Buyer, Eckert &
Ziegler will book a profit in the amount of approx. 0.6 mm EUR on the
transaction.

The background to the disinvestment is a change in the market situation for
radioactive contrast media in northern Italy. Here the margins for products
for positron emission tomography, an innovative procedure for precise
diagnosis of various cancers, has come under considerably pressure in the
last few years due to numerous new suppliers. FCI also had difficulties
with a longer break in production of the cyclotron which was operated
within the framework of a joint venture with the outpatient department of
the University of Milan.

Karolin Riehle, press relations officer for Eckert & Ziegler AG, added: 'In
Germany and the directly neighbouring countries the market for radioactive
contrast media continues to develop positively. Thanks to a network of our
own cyclotrons, strengthened partly by supply co-operations, Eckert &
Ziegler is one of the leading regional suppliers. The north Italian market
on the other hand is outside the range of this network, so that it can only
profit from these network synergies to a very limited extent.'

The Eckert & Ziegler group, which predicted a turnover of around EUR 100
million for 2009 and employs around 520 employees, is one of the largest
global suppliers of isotope technology components for radiotherapy and
nuclear medicine.

The Board of Directors

Your contact person:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations & PR
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.de

13.03.2009 Financial News transmitted by DGAP

Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf

End of News DGAP News-Service

---